BRIEF-Amgen submits supplemental biologics license application for BLINCYTO
February 14, 2017 at 09:26 AM EST
* Amgen says submits supplemental Biologics license application for Blincyto in relapsed or refractory b-cell precursor acute lymphoblastic leukemia Source text for Eikon: Further company coverage: